HCV guidance
This article was originally published in The Gray Sheet
Executive Summary
Comments are due to the agency by Jan. 6, 2000 on recently released draft guidance on premarket approval applications for assays for diagnosis or monitoring of hepatitis C that would allow use of unapproved HCV-RNA assays as corroborating evidence, as long as supporting information is provided